î
îŒ
î
Purple Biotech Ltd
PPBT0.706USD
-0.009-1.22%
çµå€Â 12/24, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
6.38Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Purple Biotech Ltd äŒæ¥å
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Purple Biotech Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãPPBT
äŒç€ŸåPurple Biotech Ltd
äžå Žæ¥Sep 03, 1978
æé«çµå¶è²¬ä»»è
ãCEOãEfron (Gil)
åŸæ¥å¡æ°9
蚌åžçš®é¡Depository Receipt
決ç®ææ«Sep 03
æ¬ç€Ÿæåšå°4 Oppenheimer St.
éœåžREHOVOT
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·7670104
é»è©±çªå·97239333121
ãŠã§ããµã€ãhttps://purple-biotech.com/
äŒæ¥ã³ãŒãPPBT
äžå Žæ¥Sep 03, 1978
æé«çµå¶è²¬ä»»è
ãCEOãEfron (Gil)
Purple Biotech Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Dr. Eric K. Rowinsky, M.D.
Dr. Eric K. Rowinsky, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Gil Efron, CPA
Mr. Gil Efron, CPA
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
Dr. Bertrand Liang
Dr. Bertrand Liang
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Arie Weber
Mr. Arie Weber
Independent Director
Independent Director
--
--
Ms. Revital Stern-Raff
Ms. Revital Stern-Raff
Independent Director
Independent Director
--
--
Dr. Hadas Reuveni
Dr. Hadas Reuveni
Founder and Chief Technology Officer of TyrNovo (a subsidiary)
Founder and Chief Technology Officer of TyrNovo (a subsidiary)
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Steven Steinberg
Mr. Steven Steinberg
Independent Director
Independent Director
--
--
Mr. Avraham Ben-Tzvi
Mr. Avraham Ben-Tzvi
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Yisrael Gewirtz
Mr. Yisrael Gewirtz
Internal Auditor
Internal Auditor
--
--
Dr. Eric K. Rowinsky, M.D.
Dr. Eric K. Rowinsky, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Gil Efron, CPA
Mr. Gil Efron, CPA
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Itzhak Israel
Mr. Itzhak Israel
Director
Director
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Thu, Nov 20
æŽæ°æå»: Thu, Nov 20
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
Virtu Americas LLC
0.53%
Citadel Advisors LLC
0.44%
GAMMA Investing LLC
0.14%
ä»ã®
89.08%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Lincoln Alternative Strategies LLC
6.51%
Orca Capital GmbH
3.30%
Virtu Americas LLC
0.53%
Citadel Advisors LLC
0.44%
GAMMA Investing LLC
0.14%
ä»ã®
89.08%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Corporation
6.51%
Investment Advisor
3.38%
Research Firm
0.77%
Hedge Fund
0.44%
Investment Advisor/Hedge Fund
0.14%
ä»ã®
88.76%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
40
355.08K
3.82%
+98.77K
2025Q2
37
55.19K
1.82%
-201.60K
2025Q1
39
103.31K
6.70%
-153.87K
2024Q4
41
133.07K
5.02%
-58.34K
2024Q3
39
222.98K
11.78%
+111.64K
2024Q2
39
147.98K
8.71%
+1.90K
2024Q1
40
184.47K
11.90%
+40.99K
2023Q4
40
174.27K
11.63%
+106.33K
2023Q3
38
64.91K
3.14%
-5.47K
2023Q2
37
13.88K
1.30%
-49.49K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Lincoln Alternative Strategies LLC
605.00K
6.7%
+605.00K
--
Sep 04, 2025
Orca Capital GmbH
306.39K
3.39%
+306.39K
--
Sep 07, 2025
GAMMA Investing LLC
12.65K
0.14%
+8.22K
+185.64%
Sep 30, 2025
BNP Paribas Securities Corp. North America
6.28K
0.07%
+900.00
+16.74%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.57K
0.05%
+100.00
+2.24%
Jun 30, 2025
UBS Financial Services, Inc.
23.14K
0.26%
+119.00
+0.52%
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
1.08K
0.01%
+275.00
+34.16%
Jun 30, 2025
Simplex Trading, LLC
53.00
0%
+53.00
--
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îéæå
æ¯ç
ããŒã¿ãªã
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Aug 13, 2020
Merger
10â1
Aug 13, 2020
Merger
10â1
æ¥ä»
çš®é¡
æ¯ç
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Sep 06, 2024
Merger
20â1
Aug 13, 2020
Merger
10â1
Aug 13, 2020
Merger
10â1
Aug 13, 2020
Merger
10â1
Aug 13, 2020
Merger
10â1
ãããã質å
Purple Biotech Ltdã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îPurple Biotech Ltdã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Lincoln Alternative Strategies LLCã¯605.00Kæ ªãä¿æããŠãããããã¯å šäœã®6.70%ã«çžåœããŸãã
Orca Capital GmbHã¯306.39Kæ ªãä¿æããŠãããããã¯å šäœã®3.39%ã«çžåœããŸãã
GAMMA Investing LLCã¯12.65Kæ ªãä¿æããŠãããããã¯å šäœã®0.14%ã«çžåœããŸãã
BNP Paribas Securities Corp. North Americaã¯6.28Kæ ªãä¿æããŠãããããã¯å šäœã®0.07%ã«çžåœããŸãã
Morgan Stanley & Co. LLCã¯4.57Kæ ªãä¿æããŠãããããã¯å šäœã®0.05%ã«çžåœããŸãã
Lincoln Alternative Strategies LLCã¯605.00Kæ ªãä¿æããŠãããããã¯å šäœã®6.70%ã«çžåœããŸãã
Orca Capital GmbHã¯306.39Kæ ªãä¿æããŠãããããã¯å šäœã®3.39%ã«çžåœããŸãã
GAMMA Investing LLCã¯12.65Kæ ªãä¿æããŠãããããã¯å šäœã®0.14%ã«çžåœããŸãã
BNP Paribas Securities Corp. North Americaã¯6.28Kæ ªãä¿æããŠãããããã¯å šäœã®0.07%ã«çžåœããŸãã
Morgan Stanley & Co. LLCã¯4.57Kæ ªãä¿æããŠãããããã¯å šäœã®0.05%ã«çžåœããŸãã
Purple Biotech Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îPurple Biotech Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Lincoln Alternative Strategies LLC
Orca Capital GmbH
Virtu Americas LLC
Lincoln Alternative Strategies LLC
Orca Capital GmbH
Virtu Americas LLC
Purple Biotech LtdïŒPPBTïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãPurple Biotech Ltdã®æ ªåŒãä¿æããŠããæ©é¢ã¯40瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ355.08Kã§ãå
šäœã®3.82%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯2.00%å¢å ããŠããŸãã
Purple Biotech Ltdã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãPurple Biotech Ltdã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
